Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer
p53 和 AXL 免疫染色对表皮生长因子突变型非小细胞肺癌患者接受奥希替尼治疗后基于免疫检查点抑制剂的治疗疗效的预测价值
期刊:Cancer Immunology Immunotherapy
影响因子:8.1
doi:10.1007/s00262-023-03370-1.
Kenji Morimoto,Tadaaki Yamada,Ryo Sawada,Koichi Azuma,Yasuhiro Goto,Taishi Harada,Shinsuke Shiotsu,Nobuyo Tamiya,Yusuke Chihara,Takayuki Takeda,Osamu Hiranuma,Isao Hasegawa,Satomi Tanaka,Akihiro Yoshimura,Masahiro Iwasaku,Shinsaku Tokuda,Young Hak Kim,Koichi Takayama
肺癌
细胞生物学
肿瘤
免疫/内分泌
AXL
P53
Checkpoint
